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1. Introduction
1.1. Definition
Periodic paralysis comprises a group of neuromuscular diseases in which the patients present
with paroxysmal muscle weakness of the limbs. [1] The most common causes are thyrotoxic
hypokalemic periodic paralysis (TPP) and familial hypokalemic periodic paralysis (FPP). [1]
Thyrotoxic periodic paralysis (TPP) is a medical emergency characterized by an acute and
reversible attack of muscle weakness associated with the hypokalemia. [1, 2] TPP is the most
common form of acquired flaccid paralysis in adults with hyperthyroidism and can occur in
patients of any ethnicity, [3, 4] although it is more frequent in Asian populations. [5] TPP is
the newest form of endocrine channelopathy included in the large group of periodic paralysis
and should be included in the differential diagnosis of acute muscle weakness in patients
seeking emergency care.
2. Epidemiology
The association of loss of limb muscle strength and Graves’ disease was first published by
Rosenfeld in the German literature at the beginning of the last century. [6] In English, the first
report was made by Dunlap and Kepler in 1931, describing four patients. [7] In 1968, the first
case of TPP diagnosed in Brazil was described by Pereira et al. [8]
TPP is more frequently described in Asian descendants, [5] but it can occur in patients of other
ancestries. [3, 4] This aspect is particularly important because TPP should not be excluded in
the differential diagnosis of paralysis based only on the patient’s ethnicity. Although thyro‐
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toxicosis has a higher incidence in women, the paralysis affects predominantly men, with a
male:female ratio of approximately 30:1. [2]
TPP symptoms occur in young adults, in contrast to FPP, in which the paralysis crises begin
at an earlier age, usually before puberty. [1] TPP is more common between the third and fifth
decades of life, which coincides with the peak incidence of thyrotoxicosis [9]. In a study
performed with 35 Brazilian patients, the age at diagnosis ranged from 19 to 51 years, [2] similar
to the international literature. [9, 10] Unlike the familial form, TPP appears as a sporadic
disease. [11] However, rare cases of TPP with a family history of paralysis and thyrotoxicosis
have been reported. [12, 13]
3. Etiology and genetic susceptibility
The paralysis crises occur only in the presence of the thyrotoxic state, regardless of its etiology.
Several causes of thyrotoxicosis with paralysis have been reported, including Graves’ disease
(GD), toxic adenoma, toxic multinodular goiter, amiodarone-induced thyrotoxicosis, TSH-
producing pituitary tumor, lymphocytic thyroiditis, and factitious thyrotoxicosis. [2] In most
of the cases, TPP is associated with the hyperthyroidism in GD, [9, 14] and the paralysis crisis
may be an atypical form of initial presentation of the disease. In our studies, there are also a
report of TPP in a patient who used formulations containing levothyroxine to lose weight. [2]
The methodological approach to determining the genetic susceptibility to TPP is difficult. This
is due in part to the absence of a familial pattern of inheritance that allows linkage analysis by
polymorphic allele markers, as almost all of the cases described in the literature are sporadic.
Second, the number of cases is relatively small, making an association study to identify genetic
susceptibility difficult. Thus, the first genes to be studied were the ones most commonly related
to FPP (CACN1AS and SCN4A) [15], a clinical condition physiopathologically similar to the
TPP. However, the investigation of these genes revealed that patients with TPP were negative
for these mutations [17, 18]. Several other genes were subsequently studied, and although there
were reports of patients bearing the KCNE3 mutation [18, 19], these patients were later proven
to have only a polymorphic variant. [20]
More recently, after the study of Plaster et al. [21] on a familial paralysis form associated with
facial dysmorphism and arrhythmias called Andersen-Twail Syndrome, a new group of
candidate genes arose. Thus, the KCNJ12 gene (potassium channel Kir2.2) was included in the
screening for TPP mutations. Kir2.2 became the candidate of greatest interest because of its
expression in the skeletal muscle and the presence of the consensus elements (cis), the Thyroid
Response Elements (TRE), in its regulatory region. Although no mutation has been found in
this group of genes in TPP, during the study of the KCNJ12 gene, a novel paralog gene was
discovered and called KCNJ18 (Kir2.6). [22] Four different mutations were identified, including
two missense (T354M & K366R) and two nonsense (R399X & Q407X) mutations that combined
are present in 33% of patients with TPP. [22] These mutations result in a defect in muscle
repolarization. The high K+levels in the muscular system keep the cell in a partially depolarized
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state, and the membrane becomes unable to trigger a new muscle excitation-contraction
coupling, resulting in flaccid paralysis. [22]
4. Physiopathology
The physiopathology of TPP remains incompletely understood. Evidence suggests that TPP
results from a combination of three factors: genetic, environmental, and thyrotoxicosis [1].
From this association, we hypothesized that the interaction of these factors would alter the
channel dynamics of the cell membrane at the neuromuscular junction, triggering the paralysis
crises only in patients genetically susceptible. [2] There are reports of a patient with history of
TPP who suffered a paralysis crisis after taking excessive doses of thyroid hormone, [23, 24]
which supports this hypothesis. [25]
In  Figure  1,  we described a  theoretical  model  of  multifactorial  interactions  in  TPP.  The
genetic  factors  could include a defect  in one of  the ion channels  involved in excitation-
contraction  coupling  (Ca2+,  Na+,  and  K+)  or  a  defect  in  one  of  the  channel’s  regulatory
subunits (ß, ∂, or SUR, for example). Alterations in one of these genes would be responsi‐
ble for the generation of non-functional ion channels, which would define the TPP as an
endocrine channelopathy. [26, 27]
The environmental factors include the excessive consumption of carbohydrate-rich foods,
alcohol, or resting after intense exercise. Thyrotoxicosis would be the limiting factor and
essential for the paralysis crisis. [1] In addition, several other studies have demonstrated that
the activity of the Na+/K+-ATPase pump is increased in thyrotoxicosis and is more exacerbated
in patients with TPP. [28, 29] The hypokalemia observed in these cases is due to the increased
K+influx into a cell secondary to the increase in the activity of the Na+/K+-ATPase pump and
by the hyperinsulinemic response to carbohydrate intake in patients susceptible to TPP. [25,
Figure 1. Theoretical model of multifactorial interaction in TPP. Modified from Ref. [1]
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30] Androgens also can increase the activity of the Na+/K+-ATPase pump, which explains the
higher incidence of the disease in young males. [30]
According to the mechanism illustrated in the Figure 2, we believe that during the TPP crisis,
the mutated Kir2.6 potassium channel retains potassium in the sarcolemma, causing hypoka‐
lemia and flaccid paralysis.
Figure 2. Physiological regulation of Kir2.6 by thyroid hormone and when mutated.
5. Clinical presentation
Illustrative case report of TPP:
A 32-year-old mulatto male patient was brought to the emergency room at 5:00 am by relatives
in a wheelchair. He reported being healthy until six months prior to presentation when
episodes of muscle weakness in his lower limbs began to develop and kept him from getting
out of bed and walking. He also complained of weakness of lower intensity in upper limbs.
He denied pain or loss of sensation. All episodes spontaneously resolved without motor
sequelae. During physical examination, a decreased in strength, especially in the lower limbs,
and hypoactive deep tendon reflexes were noted. In addition, the patient also exhibited diffuse
goiter, ocular proptosis, and thyrotoxicosis symptoms (tachycardia, excessive sweating,
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tremor of the extremities, and 10 kg weight loss). Eating several slices of pizza and soda in a
restaurant was identified by the patient as the triggering factor for the crisis the following the
next day.
The laboratory tests at the time of the crisis demonstrated hypokalemia (K=1.9 mEq/L; Normal
Range: 3.5 to 5.1 mEq/L). The ECG demonstrated the presence of “U” waves and decreased
amplitude of the T wave, and oral and intravenous potassium replacement was initiated. The
paralysis crisis was resolved after the medication, and the patient was referred to the clinic for
the etiologic diagnosis. During the investigation, Graves’ disease was diagnosed with TSH
<0.05 mUI/L (Normal range: 0.5-4.5 mUI/L), free T4 >6.0 ng/dL (Normal range: 0.6-1.5 ng/dL),
and total T3=535 ng/dL (Normal range: 30-200 ng/dL). The ultrasound revealed diffuse
enlargement of the thyroid gland and increased vascularization detected by Doppler. [1, 31] I
scintigraphy revealed an uptake of 21% over 2 hours (normal range from 1 to 8%) and 50%
over 24 hours (normal range from 3 to 23%). Methimazole and propranolol treatments were
initiated followed by the definitive hyperthyroidism therapy with radioactive iodine.
The case above illustrates the importance of a proper diagnosis to determine the specific
treatment. Many patients already exhibit signs of hyperthyroidism due to Graves’ disease
(goiter and exophthalmia) or thyrotoxicosis symptoms at the time of the paralysis crisis, but
often the thyroid alteration is not recognized at the time and may be confused with hysteria
or neuro-anxiety. Often, patients are erroneously classified as psychiatric and consequently
treated with benzodiazepines.
The paralysis crises are transient and remit spontaneously, and their frequency, duration and
intensity vary. [1] Because of this variability in the clinical presentation, the delayed diagnosis
is not uncommon. Many patients report multiple visits to the emergency department with a
sudden onset of muscle weakness of the limbs before the diagnosis.
Muscle weakness typically affects the proximal muscles of the lower limbs and is usually
symmetric. [31] Some patients may present with tetraparesis or tetraplegia, which can be
confused with Guillain-Barre syndrome, transverse myelitis, myasthenia gravis, or an acute
spinal cord compression. However, in TPP, there is no urinary incontinence or intestinal
dysfunction, nor is there a history of infection or trauma. [32] Although rare, there are reports
of respiratory muscle paralysis that requires mechanical ventilation. [1, 33] It is important to
distinguish TPP from other neuromuscular disorders that also presents with proximal muscle
weakness inherent to thyrotoxic myopathy. In these other disease, the patients exhibit muscle
atrophy and increased tendon reflexes, and the symptoms are proportional to the severity of
the thyrotoxic state. [34]
TPP may be preceded by prodromal symptoms such as muscle pain, cramps, and/or stiffness
of muscles of the affected limbs. [32] Frequently, the patients report that crises occur when
they get up during the night or early in the morning after a day of intensive exercise and/or
consumption of a large amount of food.
Sensitivity is preserved in the physical-neurological examination. However, as shown in
Figure 3, the tendon reflexes are decreased or absent in the majority of the patients, [32] in
contrast to the expected hyperreflexia in a thyrotoxic patient without paralysis. The duration
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of the crisis is variable, lasting up to 72 hours. [31] In a recently published study, the average
duration of most cases was two to six hours. [2]
Figure 3. Patellar tendon reflex in patients with TPP, normal individuals, and individuals with thyrotoxicosis.
6. Laboratory and differential diagnosis
The confirmation of thyrotoxicosis, i.e., TSH suppressed in the presence of high levels of
thyroid hormones (total and free T3 and T4), is essential for the definitive diagnosis of TPP.
Hypokalemia is the primary laboratory alteration at the time of crisis. [9, 35] There are some
reports of normokalemia, [36, 37] but we believe that these reports are due to errors during
data collection, i.e., data collection in a late stage of the crisis after the serum concentrations of
potassium have already recovered, [9] or due to improper storage of the samples, predisposing
them to hemolysis. [2]
Hypokalemia results from the influx of ion into the intracellular compartment and does not
indicate total depletion of the body potassium. [28] Calcium levels are normal, and creatine
phosphokinase (CPK) might be elevated. [2] Some patients exhibit hypophosphatemia and
hypomagnesemia, [9] both without need for replacement.
Other complementary exams, such as ultrasound, thyroid scintigraphy, and antibody meas‐
urements (anti-thyroglobulin, anti-peroxidase, and anti-TSH receptors (TRAb), may be
necessary to define the etiology of hyperthyroidism. During the paralysis crisis, some patients
exhibit a myopathic pattern on electromyography, which disappears in the remission period.
[38] Muscle biopsy demonstrates nonspecific histological findings, and the study of the
cerebrospinal fluid does not add any information to the diagnosis, both being dispensable
during the investigation of TPP. [2]
We present a table 1 summarizing the major clues for differential diagnosis of acquired
muscular disorders in young adults, including clinical and analytical features.
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Thyrotoxic
hypokalemic
periodic paralysis
(TPP)
Familial
hypokalemic
periodic paralysis
(FPP)
Guillain-Barré
syndrome Proximal myopathy
Thyrotoxicosis Yes (symptoms canbe very subtle) No No
Yes (duration rather than
severity of the thyrotoxic
state is proportional to
muscle weakness)
Age of onset
(years) 20-45 (95%) Before 16 (80%) All All
Frequency Rare Rare Rare Common (67% ofthyrotoxic patients)
Male to female
ratio 30:1 3:1 1.5:1
More common among
men
Muscle paralysis
Yes (sporadic
recurrent acute
paralysis)
Yes (sporadic
recurrent acute
paralysis)
Yes (weakness and
paralysis with
ascending
progression)
No
Ethnicity most
frequently affected East Asian White Any Any
Family history of
paralysis No Yes No No
Precipitating
factors
Heavy carbohydrate
and/or salt meal,
alcohol, exercise,
stress
Heavy carbohydrate
and/or salt meal,
alcohol, exercise,
dehydration
Usually preceded by
an infection No
Dysautonomia No No Yes No
Deep tendon
reflexes
Usually absent or
depressed
Usually absent or
depressed Absent or depressed
Normal and often
hyperactive
Severe respiratory
muscle weakness Very rare Rare 10-30% of patients
Very rare (in the acute
thyrotoxic myopathy only)
Facial muscles
weakness No No Common (≥ 50%) Very rare
Duration of muscle
symptoms 30 min-6h ≥ 24h
Progressive over days
to 4 weeks
Throughout thyrotoxic
state
Potassium level
during the muscle
symptoms
(mmol/L)
1.5-3.0 2.8-3.5 Normal Normal
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Thyrotoxic
hypokalemic
periodic paralysis
(TPP)
Familial
hypokalemic
periodic paralysis
(FPP)
Guillain-Barré
syndrome Proximal myopathy
Cerebral spinal
fluid Normal Normal
Albuminocytologic
dissociation Normal
Nerve conduction
analysis
Not specific, not
necessary Not specific
Useful and helpful for
diagnosis Not specific, not necessary
Clinical course
Remission when
euthyroidism is
reached
Chronic myopathy
Recovery; residual
deficit in up to 20%;
death in some
patients
Weakness of proximal
muscles that remits when
euthyroidism is reached
Genetic
inheritance
Mutation in KCNJ18
gene in up to 33%
of patients
Mutation in
CACN1AS gene
(80%) and SCN4A
gene (15%)
None None
(Adapted with permission from reference [2])
Table 1. Clues for differential diagnosis of acquired muscular disorders in young adults
7. Treatment and follow-up
The administration of oral and/or intravenous (IV) potassium is recommended during the
paralysis crisis to accelerate the recovery and prevent a possible cardiac arrhythmia. [2] The
oral use of potassium should be preferred, [39] but if a faster recovery is necessary, potassium
may be slowly IV infused, usually over 2 hours. The main concern about potassium replace‐
ment is rebound hyperkalemia [40] because the potassium abnormality is not due to total
potassium depletion but intracellular ion trapping. Therefore, monitoring the serum K levels
during the treatment and suspending the infusion at the first sign of the muscular force
recovery is recommended. [2]
Non-selective beta blockers, especially oral propranolol (80-240 mg/day), [2] may be useful in
TPP treatment, especially when awaiting the FT4 and TSH results, by limiting the time of the
crisis without inducing rebound hyperkalemia. [41, 42] These drugs block the adrenergic
stimulation of the Na+/K+-ATPase pump activity, resulting in lower K influx to skeletal muscle.
Early treatment for the underlying cause of thyrotoxicosis is the most important procedure in
patients with TPP. When euthyroidism is reached, the paralysis crises remits definitively. [34]
Triggering factors such as high intake of carbohydrates, alcohol, and intense physical exercise
should be avoided until the resolution of the thyroid disease. [43] In cases of thyrotoxicosis
caused by excessive intake of thyroid hormones, the drug is suspended. In hyperthyroidism
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associated with Graves’ disease, toxic multinodular goiter, or toxic adenoma, the definitive
treatment with radioactive iodine or thyroidectomy should be established immediately. Anti-
thyroid drugs (methimazole or propylthiouracil) should be prescribed as adjuvant while the
patient waits for the definitive therapy.
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